GYRE
NASDAQ
US
Gyre Therapeutics, Inc. - Common Stock
$7,12
▼ $-0,11
(-1,52%)
Vol 64K
8
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$641.7M
P/E
96,5
ROE
8,2%
Margin
6,2%
D/E
0,00
Beta
2,49
52W
$6–$14
Konsensus Wall Street
9 analis · Apr 20263
Beli Kuat
5
Beli
1
Tahan
0
Jual
0
Jual Kuat
88,9%
Peringkat Beli
Grafik Harga
Saham Serupa
BBOT
BridgeBio Oncology Therapeutics Inc
P/E 212,3
$1.0B
REPL
Replimune Group Inc
$762.5M
DSGN
Design Therapeutics Inc
$534.3M
PURR
Hyperliquid Strategies Inc
ALLO
Allogene Therapeutics Inc
$307.9M
PRME
Prime Medicine Inc
$626.4M
OCGN
Ocugen Inc
$421.6M
MDXG
MiMedx Group Inc
P/E 24,6
$1.0B
IRWD
Ironwood Pharmaceuticals Inc
P/E 19,2
$548.2M
Pendapatan
Tingkat beat: 25,0%
Laporan Berikutnya
Mei 07, 2026
Estimasi EPS: $-0,07
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $-0,07 | — | — |
| Des 2025 | $0,06 | $0,05 | $-0,01 |
| Sep 2025 | $0,03 | $0,08 | +$0,05 |
| Jun 2025 | $0,03 | $0,02 | $-0,01 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Pendapatan | — | $27.9M | $22.1M | $26.8M | $30.6M | $37.2M |
| Laba Bersih | — | -$99K | $2.7M | $442K | $3.6M | -$1.7M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 5.8% | 5.8% | 5.8% | 5.8% | 8.2% | 8.2% |
| P/E (TTM) | 155.47 | 166.17 | 167.59 | 169.01 | 110.80 | 96.48 |
| Net Margin | 1.6% | 4.1% | 4.1% | 4.1% | 6.2% | 6.2% |
| Gross Margin | 95.7% | 95.9% | 95.9% | 95.9% | 95.5% | 95.5% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.40 | 5.40 | 5.40 | 5.40 | 6.19 | 6.19 |
Rasio Utama
ROA (TTM)
4,7%
P/S (TTM)
5,98
P/B
17,9
EPS (TTM)
$0,06
CF/Share
$-18,23
Pertumbuhan Pendapatan 3T
+143,3%
52W High
$14,42
52W Low
$6,11
$6,11
Rentang 52 Minggu
$14,42
Kesehatan Keuangan
Arus Kas Bebas
-$5.8M
Utang Bersih
-$36.1M
Kas
$37.1M
Total Utang
$939K
Per tanggal Des 31, 2025
Як GYRE виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка GYRE vs аналоги Biotechnology
P/E
96,5
▲
414%
di atas
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
6,0
▼
53%
di bawah
rekan
(12,9)
vs Rekan
vs Industri
Undervalued
P/B
17,9
▲
626%
di atas
rekan
(2,5)
vs Rekan
vs Industri
Overvalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість GYRE vs аналоги Biotechnology
ROE
8,2%
▲
112%
di atas
rekan
(-67,3%)
vs Rekan
vs Industri
Tingkat atas
Net margin
6,2%
▲
102%
di atas
rekan
(-286,8%)
vs Rekan
vs Industri
Di bawah rata-rata
Валова маржа
95,5%
▲
21%
di atas
rekan
(78,6%)
vs Rekan
vs Industri
Lemah
ROA
4,7%
▲
110%
di atas
rekan
(-46,7%)
vs Rekan
vs Industri
Tingkat atas
Фінансове здоровʼя GYRE vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang rendah
Поточна ліквідність
6,2
▲
40%
di atas
rekan
(4,4)
vs Rekan
vs Industri
Di bawah rata-rata
Beta
2,5
▲
157%
di atas
rekan
(1,0)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів GYRE
GYRE
Median rekan
Industri
GYRE прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
GYRE vs аналоги: ключові метрики
Pemegang Terbesar
Top 5: 2,8%Vanguard Group Inc
1,24%
$8.1M
Blackrock Inc.
0,74%
$4.9M
Geode Capital Management, L…
0,44%
$2.9M
State Street Corporation
0,21%
$1.4M
Charles Schwab Investment M…
0,17%
$1.1M
Per tanggal Des 31, 2025
Dividen
$921,23
/ tahun
Jan 13, 2023
$3,6000
Sep 21, 2022
$21,4500
Agu 20, 2015
$896,1750
Berita Terbaru
Belum ada berita terkait